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Agonist-induced internalization of somatostatin receptors
(ssts) determines subsequent cellular responsiveness to pep-
tide agonists and influences sst receptor scintigraphy. To in-
vestigate sst2A trafficking, rat sst2A tagged with epitope was
expressed in human embryonic kidney cells and tracked by
antibody labeling. Confocal microscopical analysis revealed
that stimulation with sst and octreotide induced internaliza-
tion of sst2A. Internalized sst2A remained sequestrated
within early endosomes, and 60 min after stimulation, inter-
nalized sst2A still colocalized with -arrestin1-enhanced
green fluorescence protein (EGFP), endothelin-converting
enzyme-1 (ECE-1), and rab5a. Internalized 125I-Tyr11-SST-14
was rapidly hydrolyzed by endosomal endopeptidases, with
radioactive metabolites being released from the cell. Inter-
nalized 125I-Tyr1-octreotide accumulated as an intact peptide
and was released from the cell as an intact peptide ligand. We
have identified ECE-1 as one of the endopeptidases respon-
sible for inactivation of internalized SST-14. ECE-1-mediated
cleavage of SST-14 was inhibited by the specific ECE-1 inhib-
itor, SM-19712, and by preventing acidification of endosomes
using bafilomycinA1. ECE-1 cleavedSST-14 but not octreotide
in an acidic environment. The metallopeptidases angioten-
sin-1 converting enzyme and ECE-2 did not hydrolyze SST-14
or octreotide. Our results show for the first time that stimu-
lation with SST-14 and octreotide induced sequestration of
sst2A into early endosomes and that endocytosed SST-14 is
degraded by endopeptidases located in early endosomes. Fur-
thermore, octreotide was not degraded by endosomal pepti-
dases and was released as an intact peptide. This mechanism
may explain functional differences between octreotide and
SST-14 after sst2A stimulation. Moreover, further investiga-
tion of endopeptidase-regulated trafficking of neuropeptides
may result in novel concepts of neuropeptide receptor inac-
tivation in cancer diagnosis. (Endocrinology 149: 2200–2207,
2008)
THE TETRADECAPEPTIDE somatostatin (SST)-14 andthe N-terminally extended form, SST-28, are major in-
hibitory peptides with broad endocrine, exocrine, and neu-
ronal functions (1). sst acts via six sst receptor subtypes (sst1,
sst2A, sst2B, sst3, sst4, and sst5) that are expressed in the
central nervous system, and endocrine and immune systems.
The high density of sst receptors on neuroendocrine tu-
mors allows the use of stable sst analogs (octreotide) to in-
hibit hormonal hypersecretion (2). Moreover, this dense dis-
tribution of receptors has made the development of sst
receptor scintigraphy for tumor imaging possible (3).
Recently, we investigated agonist-induced endocytosis of
rat sst1 (4). We demonstrated that sst1 internalized after
agonist exposure. Internalized SST-14was not transported to
lysosomes for degradation but was recycled to the medium
as an intact and biologically active peptide. The ability to
internalize and recycle intact SST-14 has also been reported
for sst2A (5). In contrast to sst1, sst2A binds -arrestins with
high affinity, suggesting that sst2A belongs to the receptor
family of “class B” receptors that formprolonged interactions
with -arrestins (6).
Analysis of agonist-mediated -arrestin translocation to
multiple G protein-coupled receptors (GPCRs) has identified
two major classes of receptors. “Class A” receptors (e.g. 2
adrenergic receptor, -opioid receptor, endothelin type A
receptor, sstr3, sstr5, dopamine D1A receptor, and 1b ad-
renergic receptor) bind -arrestin2 with higher affinity than
-arrestin1 (6, 7). In contrast, “class B” receptors [e.g. angio-
tensin II type 1A receptor, neurotensin receptor 1, vasopres-
sin V2 receptor, calcitonin receptor-like receptor (CLR), TSH-
releasing hormone receptor, and neurokinin receptor 1
(NK1R)] bind both isoforms of -arrestin with similar high
affinities. “Class B” receptors are structurally characterized
by clusters of serine/threonine residues within their car-
boxy-terminal tails. They are functionally characterized by a
long-lasting sequestration after stimulation with high con-
centrations of the agonist (8, 9). Internalized “class B” re-
ceptors are sequestrated with -arrestins in hollow core ves-
icles, which are positive for the early endosome marker
proteins, early endosomal antigen-1 and rab5a (9). Recently,
we demonstrated that endothelin-converting enzyme
(ECE)-1 also colocalizes with the internalized “class B” re-
ceptors for substance P (SP) (NK1R) (10) and the receptor for
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the calcitonin gene-related peptide (CGRP) (CRL) (11). ECE-1
is a metalloendopeptidase related to neprilysin (12). Its four
isoforms (ECE-1a–d) share a catalytic domain, but differ-
ences in the cytosolic tail determine their subcellular location
(13–15). All four isoforms are present within vesicles inside
the cell, and ECE-1a as well as ECE-1c are also present at the
plasma membrane. We observed that ECE-1 degrades and
inactivates SP and CGRP. Endosomal degradation of ligands
by ECE-1 allowed recycling and resensitization of the recep-
tors. These experiments identified a new role for ECE-1 in
regulating receptor trafficking.
Recent studies of sst2A have shown that the -arrestin-
dependent trafficking of the sst2A sst receptor resembled
that of a “class B” receptor (6). Furthermore, investigation of
sst2A-mediated uptake of 125I-SST-14 did not clearly show if
the internalized ligand is released as an intact peptide or as
a metabolite of 125I-SST-14 (5). Therefore, the effects of the
natural agonist SST-14 and the peptidase-resistant and clin-
ically usefully agonist octreotide on the subcellular localiza-
tion of sst2A have not been fully evaluated, and the fate of
the endocytosed peptides are unknown.
The aim of the present study was to characterize the fate
of endocytosed sst2A and its associated ligands SST-14 and
octreotide. We found that stimulation of sst2A with SST-14
or octreotide induced internalization of sst2A and seques-
tration of the receptor within early endosomes. Internalized
125I-Tyr11-SST-14 is degraded by endosomally located pep-
tidases. Interestingly, inhibition of the activity of the endo-
somally located peptidases ECE-1 with SM-19712 or pre-
venting acidification of endosomes using bafilomycin A1
only partially inhibits degradation of SST-14, indicating that
other peptidases participate in the degradation of internal-
ized SST-14. Two iodinated metabolites of SST-14 accumu-
lated within the cell during stimulation, whereas mainly one
peptide metabolite was detected in the supernatant. Inter-
nalized 125I-Tyr11-SST-14 was not routed to lysosomes for
degradation. Interestingly, octreotide accumulated as an in-
tact peptide in the cells and was slowly released as an intact
peptide from the cells. Further investigation of the metal-
lopeptidases mediating degradation of sst showed that
SST-14 was not degraded at acidic pH or neutral pH by
recombinant human (rh) ECE-2 and rh angiotensin-1 con-
verting enzyme (ACE-1), whereas ECE-1 just degraded
SST-14 at an acidic pH. In contrast, octreotide was not de-
graded by rhECE-1, rhECE-2, or rhACE.
Materials and Methods
Materials
SST-14 and octreotide were from Bachem (Torrance, CA). 125I-Tyr11-
SST-14was fromAmershamBiosciences (Braunschweig, Germany), and
125I-Tyr1-octreotide was from Anawa (Cologne, Germany). Mouse an-
tibody to the T7 epitope was from Novagen (San Diego, CA). Donkey
antimouse coupled to fluorescein isothiocyanate or Texas Red was from
Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA). Biotin-
ylated goat anti-ECE-1 antibody, rhACE, rhECE-1, and rhECE-2 were
from R&D Systems, Inc. (Minneapolis, MN). The ECE-1 substrate
McaBK2 [(7-methoxycoumarin-4-yl)acetyl-Arg-Pro-Pro-Gly-Phe-Ser-
Ala-Phe-Lys(2,4-dinitrophenyl)], ECE-1 inhibitor SM-19712 (4-chloro-
N-[[(4-cyano-3-methyl-1-phenyl-1H-pyrazol-5-yl)amino]carbonyl] ben-
zenesulfonamide, monosodium salt), and bafilomycin A were from
Sigma Chemical Co. (St. Louis, MO). Lipofectamine 2000 was from
Invitrogen (Karlsruhe, Germany). Media, sera, and plastics were from
Life Technologies, Inc./BRL (Eggenstein, Germany). Other reagents
were from Sigma Chemical. The plasmid construct of rat sst2A con-
taining the amino-terminal T7 epitope tag sequence MASMTGGQQMG
in pcDNA3.1 has been described previously (6). Constructs for -arres-
tin1-EGFP and rab5a-EGFP were generated as described (16, 17).
Cell culture and transfection
Human embryonic kidney (HEK) 293 cells were grown in DMEM
supplemented with 10% fetal calf serum in a humidified atmosphere
containing 10% CO2. Cells were transfected using Lipofectamine 2000
according to the manufacturer’s instructions. HEK293 cells stably ex-
pressing T7-sst2A were selected in the presence of 400 g/ml G418
(Invitrogen).
Microscopy and immunofluorescence
Cells were incubated in DMEM plus 0.1% BSA with 100 nm SST-14
or octreotide for 10 min at 37 C, washed, and incubated for 0–60 min
at 37 C. Cells were fixed with 4% paraformaldehyde in 100 mm PBS (pH
7.4), for 20min. Cellswere incubated for 30min inHanks’ buffered saline
solution (HBSS), 5% normal goat serum, and 0.1% saponin. The sst2A
was detected using mouse T7 antibody (1:10,000, overnight at 4 C) and
Texas Red-conjugated goat antimouse IgG (1:200, 2 h, room tempera-
ture). -Arrestin1 and rab5a were detected using EGFP. ECE-1 was
detected using biotinylated goat anti-ECE-1 antibody (1:400) and fluo-
rescein isothiocyanate-coupled streptavidin (1:500). Cells were observed
using a 510Meta confocal microscope (Zeiss, Germany) with a Plan Apo
63 (numerical aperture 1.4) objective.
Binding assays
Cells grown in 24-well dishes were stimulated with SST-14 (100 nm)
or octreotide (100 nm) in DMEM (0.1% BSA) for 0–10 min at 37 C. Cells
were washed two times with acidic buffer [HBSS-acetic acid (pH 4.8)]
and once with HBSS (0.1% BSA). Cells were incubated for 0–120 min at
37 C, placed on ice, and incubated with 100,000 cpm 125I-Tyr11-SST-14
for 120min at 4C.Unbound 125I-Tyr11-SST-14waswashed offwithHBSS
(0.1% BSA). Cells were lysed in 1mlNaOH, and bound 125I-Tyr11-SST-14
was collected and determined in a -counter (Canberra Packard,
Dreieich, Germany) (18).
HPLC analysis of 125I-Tyr11-SST-14 and
125I-Tyr1-octreotide
Cells were incubated with 100,000 cpm/0.35 ml 25I-Tyr11-SST-14 or
125I-Tyr1-octreotide mixed with 1 nm unlabeled peptide in HBS (0.1%
BSA) for 0–15 min at 37 C. After 15-min stimulation, cells were washed
twice with warmed acidic buffer (pH 4.8) (18). In some experiments the
cells were preincubatedwith SM-19712 (10m) or bafilomycin A1 (1m)
for 30 min. Cells were washed once with HBSS (0.1% BSA), incubated
for 15 min at 37 C in 0.5 ml HBSS (0.1% BSA), washed, and incubated
for 60 min. The supernatants were collected, acidified by adding 50 l
trifluoroacetic acid (TFA) (10%), and centrifuged (5min, 13,000 g). Cell
lysates were acidified with 0.5 ml 0.08% TFA and centrifuged (5 min,
13,000  g). Samples were fractionated by reversed-phase HPLC using
a C-18 column (2 25mm). A separating gradient of 0–40% acetonitrile,
0.08% TFA, 25 min, 1 ml/min was used (HPLC-Model Akta purifier;
General Healthcare, Munich, Germany). HPLC fractions were collected
every minute and counted (4, 19, 20).
rhACE, rhECE-2, and rhECE-1 enzymatic activity
Peptidase activity was measured using McaBK2 (21). McaBK2 (6 m)
was incubated with 0.5 g rhACE, rhECE-2, or rhECE-1 in 50 mm
2-(N-morpholino)ethanesulfonic acid (pH 5.5) or 50 mm Tris/HCl (pH
7.4) at 37 C. Fluorescence was measured at  ex 320 nm and em 405 nm.
Peptide degradation by rhACE, rhECE-2, and rhECE-1
SST-14 or octreotide (250 m) was incubated with rhACE, rhECE-2,
or rhECE-1 (0.5 g) in 150 l of 50 mm (2-N-morpholino)ethanesulfonic
acid (pH 5.8) or 50mm Tris/HCl (pH 7.4) for 0–90min at 37 C. Reactions
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were stopped by boiling for 3 min. Reaction products were separated by
reversed-phase HPLC using a C-18 column equilibrated in 0.1% TFA in
water, and eluted using a linear gradient of 0.1% TFA in acetonitrile
(0–40% acetonitrile, 25 min) at 1 ml/min. Peptides were detected by
spectrophotometry (A256 nm). Products were collected and analyzed by
time-of-flight mass spectrometry.
Results
Agonists of sst2A induce receptor internalization and
association with -arrestin1
“Class B” receptors form stable and high-affinity inter-
actions with -arrestin1 and -arrestin2 at the cell surface
and in endosomes (7, 22). To further characterize the in-
ternalization of rat somatostatin receptor 2A (rsst2A), we
examined the colocalization of -arrestin1 with internal-
ized rsst2A. A fusion protein of -arrestin1 and EGFP
(-arrestin1-EGFP) and T7-rsst2A were transiently coex-
pressed in HEK293 cells (23). In unstimulated cells, -ar-
restin1-EGFP was evenly distributed in the cytoplasm and
nucleus (Fig. 1). Stimulation with SST-14 or octreotide for
10min induced translocation of -arrestin1-EGFP from the
cytosol to the cell membrane, where it colocalized with
sst2A. At later times SST-14 and octreotide induced en-
docytosis of sst2A and -arrestin1-EGFP to small vesicles
close to the cell membrane. The distribution and size of the
vesicles are similar to those found in studies analyzing
sst2A-mediated internalization of fluorescent SST-14 (24).
Internalized sst2A then translocated to hollow core vesi-
cles that also contained -arrestin1-EGFP (Fig. 1, A and B,
arrowheads). Interestingly, in cells stimulated with SST-
14, -arrestin1 is associated with internalized rsst2A (Fig.
1, A and B, arrowheads) and at the cell membrane (Fig. 1,
A and B, arrows). In cells stimulated with octreotide, -ar-
restin1 is mainly associated with internalized rsst2A. The
fluorescence intensity scan (Fig. 1, A and B, yellow arrows)
of the cells is shown in Fig. 1, E and F. The fluorescence
signal of -arrestin1-EGFP is more intensified at the
plasma membrane in cells stimulated with SST-14 (Fig. 1,
E and F, green arrows) than in cells stimulated with oct-
reotide. Thus, stimulation of rsst2A with agonist results in
translocation of -arrestin1 to the plasma membrane and
subsequent association with rsst2A for prolonged periods
indicative of a “class B” GPCR.
FIG. 1. Subcellular distribution of T7-
sst2A. HEK293 cells were transiently
transfected with T7-sst2A, -arrestin1-
EGFP (A and B) or rab5a-EGFP (C). Cells
were stimulated with 10 nM SST-14 or 10
nM octreotide, washed, and incubated for
15or60minat37C.T7-sst2Awasdetected
using amouse anti-T7 antibody andTexas
Red-conjugated antimouse antibody. -Ar-
restin1-EGFP and rab5a-EGFP were
detected with EGFP. ECE-1 was detected
using goat anti-ECE-1 antibody. In un-
stimulated cells, T7-sst2A was detected at
the cell surface.-Arrestin1-EGFPwasde-
tected as a diffuse protein located within
the cytosol. Stimulation with the peptide
ligand SST-14 for 10min induced receptor
internalization. A and B, Internalized
T7-sst2A was strongly associated with
-arrestin1. Incubation for 15 or 60
min induced the formation of hollow
core vesicles (arrowheads). -Arrestin
remained strongly associated with in-
ternalized T7-sst2A even 60 min after
cell stimulation. In cells stimulated
with SST-14, -arrestin1 is also lo-
cated at the cell membrane (arrows).
The yellow arrows show the area of
the intensity scans. C, Colocalization
of internalized T7-sst2A with rab5a-
EGFP 60 min after cell stimulation
with SST-14 (10 nM), indicating the
localization of internalized T7-sst2A
in early endosomes. D, Colocalization
of internalized T7-sst2A with endog-
enously expressed ECE-1 60 min after
stimulation of the cells with SST-14
(10 nM). Fluorescence intensity scan of
cells stimulated with SST-14 (E) and
octreotide (F) after 60 min recovery.
The fluorescence signal of -arres-
tin1-EGFP is more intensified at the
plasma membrane (green arrows) in
cells stimulated with SST-14 than in
cells stimulated with octreotide.
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Internalized rsst2A is sequestrated in early endosomes
After stimulation with agonist, “class B” GPCRs such as
NK1R, CLR, and angiotensin II type 1A receptor are seques-
trated within early endosomes for prolonged periods (9, 25,
26). To determine the subcellular location of internalized
rsst2A, HEK293 cells were transiently transfected with T7-
rsst2A and a marker protein for early endosomes, rab5a-
EGFP, and their localization was examined using immuno-
fluorescence and confocal microscopy. In unstimulated cells,
rsst2A was present at the plasma membrane, and rab5a was
present in vesicles within the cell (data not shown). After
stimulation with SST-14 (10 nm, 10 min) and incubation in
SST-14-free medium for 60 min, internalized rsst2A colocal-
ized with rab5a-EGFP in small and hollow core vesicles (Fig.
1C, arrowheads). Thus, after stimulation with SST-14, rsst2A
traffics to early endosomes and remained there for at least 60
min after stimulation.
Internalized rsst2A colocalizes with endogenous ECE-1
HEK293 cells endogenously express all four isoforms of
ECE-1 (10). Within the acidic environment of early endo-
somes, ECE-1 has inactivated the peptide ligands of some
“class B” GPCRs (10, 11). We have previously demonstrated
that SP and CGRP are inactivated by ECE-1 endogenously
expressed by HEK293 cells. HEK293 cells were transiently
transfectedwith rsst2A and the receptor and ECE-1 localized
by immunofluorescence and confocal microscopy. In un-
stimulated cells, rsst2A was localized at the plasma mem-
brane, and ECE-1 was distributed in cytoplasmic vesicles.
After stimulation rsst2A was localized at the plasma mem-
brane and colocalized with ECE-1 in vesicles. Thus, rsst2A is
transported from the plasma membrane to early endosomes
where it remains colocalized with ECE-1 (Fig. 1D).
Recovery of agonist-binding sites after sst2A stimulation
Another characteristic of “class B” GPCRs is that they
slowly recycle back to the cell surface because they were
sequestrated within early endosomes. Confocal micro-
scopical analysis of sst2A expressed in rat insulinoma cell
line 1046–38 or in HEK293 cells suggests that sst2A recy-
cled to the plasma membrane within 1–2 h (6, 18). There-
fore, we analyzed sst2A recycling by determining the re-
appearance of cell surface binding sites after stimulation
with SST-14 or octreotide. Rat sst2A-HEK293 cells were
stimulated with SST-14 or octreotide, and the recovery of
surface binding sites was determined by incubation with
125I-SST-14. We found that stimulation with SST-14 or
octreotide rapidly induced a marked reduction of surface
binding sites (Fig. 2). After stimulation (10 min, 37 C),
surface binding sites of SST-14 (51  3%) and octreotide
(45 4%) were markedly reduced. Interestingly, the bind-
ing sites did not recover during 2-h incubation at 37 C.
These findings indicate that sst2A remained internalized
for at least 2 h after stimulation with both peptide ligands.
This slow recovery of binding sites is indicative of the
classical trafficking of a class B GPCR.
Internalized 125I-Tyr11-SST-14 but not 125I-Tyr1-octreotide
is degraded by endosomal endopeptidases
Because the receptor-ligand complex of “class B” receptors
is sequestrated within acidic early endosomes, endosomal
located peptidases are capable of mediating the degradation
of the endocytosed peptide ligands (10, 11). We analyzed the
degradation of 125I-SST-14 and 125I-octreotide in HEK293
cells stably expressing sst2A. Cells were incubated for 0–15
minwith 100,000 cpm radiolabeled peptide, mixedwith 1 nm
unlabeled peptide in HBSS (0.1% BSA) at 37 C, washed twice
with acidic HBSS (pH 4.8), and once with HBSS (0.1% BSA),
and incubated for 0–90 min at 37 C. Cell lysates and super-
natants were collected and analyzed by HPLC. Analysis of
cell lysates from SST-14-treated cells indicates that SST-14
was rapidly endocytosed by sst2A-HEK293 cells (Fig. 3A,
closed diamonds). SST-14 was rapidly degraded into two
radioactive labeled peptide metabolites that accumulated
within the cell. After 15-min incubationwith 125I-SST-14, only
42.9% of total radioactivity was found to be cell associated as
intact 125I-SST-14. Of the remaining radioactivity, 19.3% was
peptide A (retention time, 9 min), and 37.7% was peptide B
(retention time, 11 min) (Fig. 3A). Incubation for longer pe-
riods at 37 C induced further degradation of the internalized
SST-14. At 90 min after stimulation, only 7.3% of the total
radioactivity remained as intact SST-14, whereas 13.7% of the
total radioactivity was peptide B, and 2.6% of the total ra-
dioactivity was peptide A. Interestingly, most of the radio-
activity was released from the cells (Fig. 3C). HPLC analysis
of supernatants demonstrated that two peptide metabolites
were released from the cells. The major product was peptide
B (69.2% of the total radioactivity), with the minor product,
peptide A, only being 4.9% of the total radioactivity. The
small amount of peptide A detected into the supernatant
(4.9%, even after 90min) is inmarked contrast to themaximal
amount associated with the cell after 15 min (19.3% of total
radioactivity). These findings suggest that peptide A is an
intermediate degradation product before being further pro-
cessed to peptide B.
We found that incubation of sst2A cellswith 125I-octreotide
FIG. 2. Agonist-induced loss of cell surface binding sites. HEK293
cells stably expressing T7-sst2A were stimulated for 10 min with
SST-14 (100 nM) (squares) or octreotide (100 nM) (diamonds). Cells
were washed with acidic buffer to remove extracellular ligands, and
were incubated for 0, 60, and 120 min at 37 C. Cells were set on ice,
and recovery of surface binding sites was determined using 125I-SST-
14. Surface-binding sites did not recover 120 min after washing the
cells. The binding sites remain at approximately 50% of unstimulated
cells.
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induced accumulation of intact octreotide in the cells (Fig.
3B). Ninety minutes after cells were washed, 83% of the
internalized octreotide was still cell associated, and 17% of
the radioactivity was found in the supernatant as intact oc-
treotide (Fig. 3D).
As shown in a representative HPLC chromatogram (Fig.
3E), intact 125I-Tyr11-SST-14 eluted by 16 min, and two ra-
dioactive degradation products (peptide A and peptide B)
were recognized by HPLC as having eluted by 9 and 11 min,
respectively. The 125Tyr eluted by 3–4 min and could not be
detected in the cell lysate or the supernatant of rsst2A-HEK
cells, indicating that SST-14 was not routed to lysosomal
degradation (11).
HEK293 cells endogenously express all four isoforms of
ECE-1 (10). Therefore, in our next set of experiments,we tried
to inhibit intracellular degradation of internalized 125I-
SST-14 by preincubating the cells with the ECE-1-specific
inhibitor, SM-19712 (10 m), and by neutralizing acidic ves-
icles by preincubating with bafilomycin A1 (1 m). Both
inhibitors had been previously tested for the ECE-1-medi-
ated degradation of internalized SP and CGRP (10, 11). We
preincubated cells for 15 min with 100,000 cpm 125I-Tyr11-
SST-14 mixed with 1 nm SST-14 in the presence of the in-
hibitors, washed, and incubated the cells for 60 min at 37 C.
Without inhibitor, 7.3% (4) of the total radioactivity was
intact 125I-Tyr11-SST-14. In cells preincubatedwith SM-19712,
24 3%of the total radioactivitywas intact 125I-Tyr11-SST-14,
and in cells pretreated with bafilomycin A1, 26  4% was
intact 125I-Tyr11-SST-14 (Fig. 3F). These findings indicate that
SM-19712 significantly blocked the intracellular degradation
of 125I-Tyr11-SST-14 and that the degradation is sensitive to
neutralization of acidic vesicles. Interestingly, whereas the
intracellular degradation of SP or CGRP could be almost
completely blocked with SM-19712 and bafilomycin A1 (10,
11), the degradation of 125I-Tyr11-SST-14 was only partially
blocked with the inhibitors, indicating that besides ECE-1,
FIG. 3. Fate of internalized radiolabeled SST-14
and octreotide (octre). HEK293 cells stably ex-
pressing T7-sst2A were incubated for 5, 10, and
15 min with 125I-SST-14 (100,000 cpm) mixed
with unlabeled SST-14 (1 nM) (A and C) or with
125I-octreotide (100,000 cpm) mixed with unla-
beled octreotide (1 nM) (B and D). Cells were
washed with an acidic buffer and incubated for
30, 60, and 90 min at 37 C. Radioactivity in the
supernatant and cells was analyzed by HPLC.
Internalized 125I-SST-14 (closed diamonds) was
rapidlydegradedbypeptidasesduring15-min in-
cubation with the ligand. The amount of cell-as-
sociated intact SST-14 decreased to 42.9%. Fur-
ther incubation at 37 C allowed degradation of
internalized SST-14 after 90-min incubation. Of
the total radioactivity, 7.3% was intact 125I-SST-
14. A, Two radioactive degradation products ac-
cumulated in the cells (closed trianglesand closed
circles)duringtheincubationwith125I-SST-14.C,
The degradation products were rapidly released
from the cells. Intact 125I-SST-14 was not de-
tected in the supernatant. The degradation prod-
uct with the retention time of 11 min was the
major degradation product detected in the super-
natant. B, During incubation of cells, octreotide
accumulatedasan intactpeptidewithin thecells.
No degradation products were detected as cell
associated. After washing, the amount of cell-as-
sociated octreotide decreased to 83%. D, Only in-
tact octreotide was detected in the supernatant.
No degradation products of octreotide were de-
tected in the supernatant. E, A representative
HPLC profile of cell-associated 125I-SST-14 after
5-min incubation with 125I-SST-14. F, The influ-
ence of theECE-1 inhibitorSM-19712andbafilo-
mycin A on the degradation of 125I-SST-14. Cells
werepretreatedwithSM-19712 (10M)orbafilo-
mycin A (1 M) for 30 min, stimulated with 125I-
SST-14 for 15min, washed, and incubated for 60
min in the presence of the inhibitors. In control
cells, 7.3% of the total radioactivity was intact
SST-14. In cells pretreated with SM-19712, 24%
of the total radioactivity was intact SST-14. In
cells pretreated with bafilomycin A, 26% of the
total radioactivitywas intactSST-14.**,P0.01
to control. G, The sequences of SST-14 and oct-
reotide. The peptides were digested with
rhECE-1, and the products were purified by
HPLC and identified by mass spectrometry.
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other endopeptidases participate in the endosomal degra-
dation of SST-14. Figure 3G shows the sequences of SST-14
and octreotide. The arrows mark the sites of cleavage by
ECE-1 inferred from the product masses.
We next sought to determine whether other endopepti-
dase were able to degrade SST-14. Therefore, we tested
rhECE-1, rhECE-2, and rhACE-1 to see if they degraded
SST-14 and octreotide. The activity of the metallopeptidases
was measured with the synthetic fluorescence substrate
McaBK2.We tested the degradation ofMcaBK2 at neutral pH
and at pH 5.8, which is equal to the pH of acidic early
endosomes (10). The metallopeptidases are active at pH 5.8
(data not shown). At neutral pH, rhACE degrades McaBK2
10 times faster than at pH 5.5, whereas rhECE-2 did not
degrade McaBK2 at pH 7.4 (data not shown). While testing
the degradation of SST-14 and octreotide, we found that
ECE-1 did not degrade octreotide in an acidic environment
but did degrade SST-14 (Fig. 4, A and B). Time-of-flight mass
spectroscopy showed that SST-14 was degraded at position
Asn 5-Phe6 and at position Thr10-Phe11, leading to two deg-
radation products: the peptide SST-14 (1–5)–SST-14 (11–14)
and to SST-14 (6–10).
Figure 4C shows the time course of rhECE-1 mediated
degradation of SST-14 in an acidic and neutral environment.
At pH 5.8, rhECE-1 rapidly degraded SST-14. After 30-min
incubation, 50% of the SST-14 was degraded. Interestingly,
prolonged incubation with rhECE-1 did not result in a com-
plete degradation of the peptide. A similar incomplete deg-
radation profile was observed for the ECE-1 mediated deg-
radation of CGRP (11).
Figure 4D shows the amount of intact peptide for oct-
reotide and SST-14 after 90-min incubation with rhECE-1,
rhECE-2, and rhACE. Of note, octreotide was not degraded
by any of these endopeptidases. SST-14 was only degraded
by ECE-1 in an acidic environment by approximately 50%
(Fig. 4D). None of the other tested endopeptidases hydro-
lyzed SST-14.
Discussion
The first aim of this investigation was to determine the
subcellular localization of internalized sst2A. Our results
show that stimulation with SST-14 or octreotide induced
internalization of sst2A into early endosomes. Even 60 min
after stimulation, sst2A still colocalized with the early en-
dosomal marker protein rab5a. These results, including the
strong association of internalized rsst2A with -arrestin1-
EGFP, indicate that sst2A trafficking resembles the traffick-
ing mechanism of a “class B” receptor (9, 26). Interestingly,
-arrestin1 is located at the cell membrane and at early en-
dosomes when the cells are stimulated with SST-14, whereas
-arrestin1 is mainly associated with early endosomes after
stimulation with octreotide. The data let us suggest that
degradation of SST-14 allowed dissociation of -arrestin1
from internalized rsst2A and translocation of -arrestin1 to
the cell membrane. Our results are in line with previous
results analyzing -arrestin trafficking and endosomal sort-
ing of other sst receptors subtypes (6, 18). Interestingly,
whereas confocal analysis of the recycling behavior of sst2A
in rat insulinoma 1046–38 cells or HEK293 suggests that
sst2A recycled within 1–2 h, we were unable to observe
recycling of rsst2A 60 min after stimulation. That we were
able to determine the reappearance of surface binding sites
indicates that sst2A did not recycle 2 h after stimulation with
the cognitive ligand.
Another characteristic of “class B” GPCRs is the formation
of hollow core vesicles. This has been clearly demonstrated
for the AT(1A)R and the NK1R (9, 26). Hollow core vesicles
are enlarged vesicles, which are formed by the constitutively
active rab5a mutant rab5aQ79L. Other studies found that
rab5a is a binding protein of the AT(1A)R and suggested that
FIG. 4. Degradation of SST-14 and oc-
treotide with rhACE, rhECE-2, and
rhECE-1. A, The HPLC profile of oct-
reotide (250 M) incubated with ECE-1
(0.5 g) for 90 min at 37 C (pH 5.8).
Octreotide was not degraded by ECE-1.
B, The HPLC profile of SST-14 incu-
batedwithECE-1 for 90min at 37C (pH
5.8). C, The time dependence of ECE-
1-mediated degradation of SST-14 at
pH 5.8 and pH 7.4. At neutral pH,
ECE-1 did not degrade SST-14. SST-14
was rapidly degraded by ECE-1 at pH
5.8. After 30-min incubation, 47% of
SST-14 was degraded. Longer incuba-
tion of the peptide with ECE-1 did not
result in further degradation of the pep-
tide. D, The degradation of octreotide
and SST-14 by rhACE, rhECE-2, and
rhECE-1 at a neutral pH (gray bars)
and at pH 5.8 (black bars). Only SST-14
was degraded by ECE-1 in an acidic en-
vironment.
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an intrinsic guanosine 5-diphosphate-guanosine 5-triphos-
phate (GTP) exchange element is encoded in the carboxy-
terminal tail of the AT(1A)R (25, 26). The direct interaction
of phosphorylated receptor and activated (GTP-bound)
rab5amay lead to the homotypical fusion of early endosomes
and the subsequent formation of hollow core vesicles. A
detailed analysis of deletion mutants of AT(1A)R demon-
strated that truncation of the C-terminal tail of the receptor
inhibits the formation of hollow core vesicles but does not
inhibit internalization of the receptor (26). Previous studies
showing that the guanosine 5-diphosphate-GTP-exchange
element is coded at the far end of the C terminus of the
AT(1A)R let us suggest that the naturally occurring splice
variant of sst2, sst2B, demonstrates a different pattern of
internalization, resensitization, and trafficking compared
with sst2A (27, 28).
Our confocal microscopic observation of T7-rsst2A and
-arrestin1-EGFP also shows that stimulation with SST-14
and octreotide induced the formation of -arrestin1 and
coated hollow core vesicles. These results indicate that rsst2A
trafficking is blocked in early endosomes. The localization
within early endosomes could be also demonstrated by the
colocalization of internalized rsst2A with rab5a-EGFP. Be-
cause the receptor is not immediately transported to late
endosomes, and the ligand is not routed into lysosomal deg-
radation, endopeptidases with an acidic pH optimum for
degradation of small peptides, like ECE-1 or ECE-2, should
be involved in the hydrolysis and inactivation process of the
endocytosed peptide ligands (29, 30). Recently, the endo-
peptidase ACE was also cotransported with internalized re-
ceptors (31), suggesting that this degrading enzyme may not
necessarily be constitutively locatedwithin early endosomes.
The degradation of an internalized peptide agonist by early
endosomally located endopeptidases was recently demon-
strated for the NK1R/SP and for the CLR/CGRP system (10,
11). The same studies showed that for both class B receptors,
intracellular ECE-1 inactivates the internalized ligandwithin
early endosomes and allowed dissociation of -arrestin1
from the internalized receptor. They also showed that the
degradation of ligand by ECE-1 is an essential step in the
process of neuropeptide receptor trafficking and resensiti-
zation. In particular, ECE-1 cleaved SP at positions Gln
6–Phe7 and Gly9–Leu10 to form the metabolites SP[1–6] and
SP[1–9]. Similar to the degradation of SP and CGRP, that of
SST-14 by ECE-1 is also sensitive to a specific pH.
The metabolites of ECE-1-mediated degradation of SP,
SP[1–6] and SP[1–9], accumulated within the cells and were
slowly released into the supernatant. In contrast, the metab-
olites of CGRP transiently occurredwithin the cells andwere
most probably transported toward lysosomal degradation.
Here, we demonstrate that the preferred cleavage sites of
SST-14 are at positions Asn5–Phe6 and Thr10–Phe11. ECE-1
hydrolyzed peptides N terminal from hydrophobic amino
acids. Thus, SST-14 has four potential degradation sites for
ECE-1. The degradation analysis of 125I-Tyr11-SST-14 re-
vealed that internalized 125I-SST-14 was processed to two
radioactively labeled products, suggesting that ECE-1
cleaved 125I-SST-14 at two positions. One of these degrada-
tion products accumulateswithin the cell, and, subsequently,
only parts of this product could be detected in the superna-
tant after prolonged incubation.
It is unknown whether the intermediate peptide is further
processed by hydrolysis or by a reduction/oxidation process
of the peptide. Intermediate degradation products, which are
further degraded by hydrolysis, were reported for the ECE-
1-mediated degradation of internalized SP and CGRP (10,
11). However, the reduction of the peptide will release the
hydrophilic N-terminal part of SST-14 (AGSKN) from the
hydrophobic radioactively labeled C-terminal end. This fact
can explain the prolonged retention time of the major deg-
radation product. Oxidation of the intermediate peptide also
has an impact on the retention time. Following this hypoth-
esis, it remains uncertain if 125I-SST-14 is specifically hydro-
lyzed at two positions or, alternatively, is merely hydrolyzed
once and further converted by a reduction or oxidation pro-
cess that may occur in the supernatant during the incubation
time at 37 C.
Because iodination of the tyrosine changes the elution time
of the peptide, we were unable to determine the sequence of
the iodinated degradation product. Our inability to detect
125-I-Tyr as a degradation product suggests that SST-14 is not
transported to lysosomal degradation. In support of these
findings, others have shown that sst2A stimulation in Chi-
nese hamster ovary cells leads to the release of the radiola-
beled agonist as an iodinated peptide (5). However, in these
studies the degradation products were not analyzed by
HPLC. Therefore, it was still unknown whether or not the
peptide was released as an intact peptide or as a metabolite.
The release of intact SST-14 was recently reported for sst1.
Therefore, it was important to determine the fate of inter-
nalized SST-14 by HPLC (4). Our experiments clearly dem-
onstrate that SST-14 was not released as an intact peptide,
whereas the synthetic peptide, octreotide, accumulated as an
intact peptidewithin the cells andwas subsequently released
as an intact peptide from the cells. We further showed that
rsst2A internalizes and colocalizes with ECE-1 within early
endosomes. Furthermore, ECE-1 was able to degrade SST-14
in an acidic environment of early endosomes, but not at a
neutral pH.
In our study, preventing acidification of endosomes with
bafilomycin A1 or inhibition of ECE-1 activity by SM-19712
prevented the intracellular degradation of SP and CGRP,
whereas the intracellular degradation of SST-14 was only
partially blocked by inhibitors. This observation strongly
suggests also that other endopeptidases besides ECE-1 par-
ticipate in the endosomal degradation process of SST-14.
Therefore, we tested whether rhECE-2 and rhACE were able
to degrade SST-14 and octreotide. Interestingly, both pepti-
dases were unable to degrade SST-14. Alternatively, an en-
dosomal location for cathepsin B has been recently reported
(32). Therefore, we tested whether the cathepsin B inhibitor,
CA074-ME, was able to prevent endosomal degradation of
SST-14. In fact, pretreatment of cells with CA074-ME before
SST-14 stimulation did not influence the endosomal degra-
dation of SST-14 (data not shown).
In the present study, we compared the fate of a natural
ligand, SST-14, and the long-lasting synthetic sst analog oc-
treotide in cells expressing rsst2A. Both peptides induced
internalization and sequestration of sst2A within early en-
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dosomes. In early endosomes, SST-14 was hydrolyzed and
inactivated by different endopeptidases. The endopeptidase-
generated degradation products were released as peptide
fragments from these cells. At the same time, the internalized
receptor remained intracellularly located and was not recy-
cled. Furthermore, the synthetic analog (octreotide) re-
mained as an intact ligand for a prolonged time within the
cells, where it colocalized with the internalized receptor
sst2A. The finding that an internalized ligand of sst2A can be
degraded within early endosomes while not routed into ly-
sosomal degradationwill help to develop novel radiolabeled
sst or other neuropeptide ligand analogs useful for medical
diagnostics such as tumor imaging as well as molecular
imaging for in vivo models of inflammation (33, 34).
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